CD274 and small cell lung carcinoma: In contrast, the general hypothesis in the case of nivolumab is that PD-L1 expression cannot be considered a unique criterion for predicting and determining the appropriate patient population that will have a good response to anti-PD-L1 antibody treatment, as the clinical benefit of immunotherapeutic agents has also been observed in patients with PD-L1 negative SCLC (30, 31, 51–53, 65, 71, 77–79).